UBS analyst AJ Rice raised the firm’s price target on Tenet Healthcare (THC) to $230 from $217 and keeps a Buy rating on the shares. Labor efficiencies drove a fundamental outperformance, and the runway remains high for the high-acuity ambulatory surgery center strategy, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $180 from $165 at Guggenheim
- Tenet Healthcare price target raised to $171 from $161 at Barclays
- Tenet Healthcare’s Strategic Expansion and Strong Financial Performance Highlighted by Conservative Guidance and Robust Margins
- Tenet Healthcare Reports Strong Q1 2025 Results
- Tenet Healthcare’s Strong Q1 Performance Amid Policy Uncertainty